The 2023/2024 season quadrivalent influenza vaccine manufactured by Sanofi has been delivered to pharmacies and private clinics.
According to Sanofi in its press release, the influenza vaccine supplied to Ukraine is suitable for protecting adults, including pregnant women, as well as adolescents and children aged 6 months and older. In addition, it provides passive protection for infants up to 6 months of age when administered to pregnant women.
According to Anna Pastushyna, Head of Sanofi Vaccines in Ukraine, the 2022/2023 season saw an increased demand for vaccines due to the high prevalence of influenza after the easing of COVID-19 restrictions.
“The company plans to fulfill its obligations to supply influenza vaccine in the countries where it operates,” she emphasized.
For his part, Fedir Lapiy, head of the National Technical Group of Experts on Immunization, noted that “influenza can worsen a number of pre-existing chronic respiratory disorders, including asthma and chronic obstructive pulmonary disease.”
“Adults over the age of 40 are eight times more likely to have a first stroke after being infected with influenza, while in children under 14, influenza increases the risk of pneumonia eightfold. Almost every third elderly person hospitalized with influenza develops pneumonia. And for people with diabetes, the risk of hospitalization during the flu epidemic is six times higher,” he said.
As reported, according to the Center for Public Health (CDC), 3.9 million cases of influenza and more than 140 thousand hospitalizations caused by the influenza virus were reported during the previous flu season of 2022/2023 (from September 2022 to April 2023).
“Sanofi is an innovative global healthcare company operating in 100 countries.
As reported, 151,100 thousand doses of the French influenza vaccine and 114.6 thousand doses of the Korean vaccine will be supplied in the 2023/24 epidemic season.
The commercial cassation court of the Supreme Court of Ukraine has supported the pharmaceutical distributor of Ukrainian-Estonian joint venture Optima-Pharm Ltd. in the lawsuit against the Antimonopoly Committee of Ukraine regarding Sanofi pharmaceutical company. The authorized government official at the Antimonopoly Committee of Ukraine, Svitlana Panaiotidi, gave this information. “Today we lost the Supreme Court case. It was the lawsuit of the Optima-Pharm distributor in the Sanofi case,” she wrote on her Facebook page on Tuesday.
As reported, in September 2018, Kyiv’s business court of appeals upheld the ruling of the court of lower instance, which satisfied a claim of the distributor of medicines Optima-Pharm LLC against the Antimonopoly Committee of Ukraine regarding the annulment of a fine of UAH 40.759 million imposed for anticompetitive actions committed jointly with Sanofi-Aventis Ukraine LLC. According to the ruling issued on September 4, 2018, the panel of judges of the appeal court agreed with the conclusion of the court of lower instance that the committee when making decision No. 628-r did not clarify the circumstances in full.
In October 2018, Kyiv’s business court has overturned the decision of the Antimonopoly Committee of Ukraine to collect the UAH 70 million fine from Sanofi pharmaceutical company.
In 2017, the Antimonopoly Committee of Ukraine fined Sanofi-Aventis Ukraine and its distributors BaDM LLC and Optima-Pharm LLC in the total amount of UAH 139.094 million for supplies of medicines in 2020-2011.
